
AbbVie (ABBV) Stock Forecast & Price Target
AbbVie (ABBV) Analyst Ratings
Bulls say
AbbVie is a global biopharmaceutical company that focuses on immunology, oncology, neuroscience, and aesthetics. With a strong portfolio of blockbuster drugs such as Humira, Skyrizi, and Rinvoq, acquisitions of Allergan, Cerevel, and ImmunoGen, and a robust pipeline, the company is poised for continued growth. Additionally, AbbVie's board-level Public Policy and Sustainability Committee ensures responsible pricing decisions and sustainable long-term strategy. Despite challenges such as government pricing pressures and product liability risks, the company has a strong track record of diversity and governance. With a buy rating and a price target of $261, AbbVie is a promising investment opportunity.
Bears say
AbbVie is facing biosimilar competition in the immunology segment, leading to potential erosion in sales of Humira, its flagship product. Despite acquired products in aesthetics and neuroscience, the company faces pipeline risks and patent challenges. With a P/E multiple of 15x, lower than peers, and a 16.5% EPS growth, the stock is trading at a discount, but the negative outlook is based on increasing competition and macro conditions leading to potential rotation away from defensive stocks.
This aggregate rating is based on analysts' research of AbbVie and is not a guaranteed prediction by Public.com or investment advice.
AbbVie (ABBV) Analyst Forecast & Price Prediction
Start investing in AbbVie (ABBV)
Order type
Buy in
Order amount
Est. shares
0 shares